Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015

NCT03283761 is registered in ClinicalTrials.gov with Al B. Benson, III, MD as lead sponsor.

NCT NCT03283761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03283761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
Lead sponsor
Al B. Benson, III, MD
Phase
Phase 2
Overall status
Completed
Start date
September 21, 2017
Completion date
January 16, 2023
Enrollment
39 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastro-esophageal junction adenocarcinoma